AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27374467
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan and salvage ASCT
Trial: 27374467
Drug: Weekly oral
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly oral cyclophosphamide
Trial: 24679060
Drug: Intensive medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medical therapy plus Roux-en-Y gastric bypass
Trial: 24679060
Drug: Intensive medical
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive medical therapy plus sleeve gastrectomy
Trial: 17611340
Drug: Quadruple fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple fluid aerosol inhalation before radiotherapy
Trial: 17611340
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional oral care)
Trial: 7599918
Drug: Caffeine 2.1
RxNorm normalized name: caffeine 2.17 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 2.1 mg*kg‐1 body weight
Trial: 7599918
Drug: Caffeine 4.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 4.3 mg*kg‐1 body weight
Trial: 7599918
Drug: Caffeine 8.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 8.6 mg*kg‐1 body weight
Trial: 31504798
Drug: Active screening
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active screening group (annual invitation for low-dose computed tomography for 4 years)
Trial: 21890090
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ischemia and VT
Trial: 15927929
Drug: Tomatoes cooked
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomatoes cooked with olive oil (25 ml); 470 g per meal for 5 days
Trial: 15927929
Drug: Tomatoes cooked
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomatoes cooked without olive oil; 470 g per meal for 5 days
Trial: 10333123
Drug: Combined diphtheria-tetanus-acellular
RxNorm normalized name: acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Boostrix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus vaccine
Trial: 10333123
Drug: Hiberix, ActHib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hiberix, ActHib, Pedvax, HibTITER (Hib conjugate vaccines)
Trial: 8949976
Drug: Long-term therapy
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term therapy to improve glucose control
Trial: 1754753
Drug: Pivampicillin 700
RxNorm normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin 700 mg twice daily for 7 days
Trial: 31222796
Drug: Chlorzoxazone 500
RxNorm normalized name: chlorzoxazone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorzoxazone 500 mg
Trial: 31222796
Drug: Chlorzoxazone microdose
RxNorm normalized name: Chlorzoxazone
DrugBank: Chlorzoxazone (DB00356)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorzoxazone microdose (0.05-500 mg)
Trial: 31222796
Drug: Chlorzoxazone microdose
RxNorm normalized name: Chlorzoxazone
DrugBank: Chlorzoxazone (DB00356)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorzoxazone microdose (≥50 mg)
Trial: 27539026
Drug: Reading on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reading on a self-luminous tablet
Trial: 17650790
Drug: Guben Yiliu
RxNorm normalized name: MENTHOL 3 g TRANSDERMAL PATCH [TIANHE GUBEN YAOSHEN TIE GAO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guben Yiliu II (GY II) combined with arterial perfusion with chemotherapeutic agent
Trial: 17650790
Drug: Chemotherapeutic agent
RxNorm normalized name: Other chemotherapeutics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapeutic agent alone
Trial: 7866915
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of oral calcium
Trial: 7866915
Drug: 200 IU
RxNorm normalized name: Vitamin E 200 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 IU of intranasal calcitonin
Trial: 7866915
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control session)
Trial: 2547245
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin for three months in addition to conventional local therapy (N=18)
Trial: 2547245
Drug: Conventional local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional local therapy (Control group, N=8)
Trial: 28053158
Drug: Bioengineered bilayered
RxNorm normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioengineered bilayered living cellular construct (BLCC) skin substitute together with standard of care (compression therapy)
Trial: 28053158
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (compression therapy)
Trial: 21457668
Drug: Oral alpha-lipoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral alpha-lipoic acid (ALA) 1200 mg/day for 8 weeks
Trial: 21457668
Drug: Placebo 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1200 mg/day for 8 weeks
Trial: 16517331
Drug: Group P
RxNorm normalized name: High mobility group protein HMGI-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group P - preoperative placebo tablet, propofol induction, propofol-air/O2 maintenance
Trial: 16517331
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I + O - preoperative 8-mg ondansetron tablet, thiopental induction, isoflurane-N2O maintenance
Trial: 16517331
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I (control) - preoperative placebo tablet, thiopental induction, isoflurane-N2O maintenance
Trial: 8888927
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (delaying physiotherapy until abnormal physical signs became apparent)
Trial: 30896976
Drug: Involved R/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Involved R/L IKDC‐SKF
Trial: 30896976
Drug: R/L IKDC‐SKF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R/L IKDC‐SKF
Trial: 27485060
Drug: Rowachol 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rowachol 100 mg orally three times daily for 3 months after surgery
Trial: 21680781
Drug: Quercetin 500
RxNorm normalized name: quercetin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 500 mg once a day for 13 days
Trial: 19301734
Drug: Sequential boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential boost (15 Gy/5F)
Trial: 17461530
Drug: 40mL of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mL of 300mg ropivacaine with 1:200,000 epinephrine and 5mg morphine
Trial: 15200445
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate 50 mg administered 2 hours before hemodialysis
Trial: 15200445
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate 50 mg administered 2 hours after hemodialysis
Trial: 12473004
Drug: Cilostazol 50
RxNorm normalized name: cilostazol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 50 mg bid or 100 mg bid for 12, 16, or 24 weeks
Trial: 11440349
Drug: Tiagabine (TGB),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (TGB), dosage up to 64 mg/day
Trial: 9402169
Drug: Cisplatin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (50 mg/m2), Epirubicin (70 mg/m2), Paclitaxel (175 mg/m2 over three hours)
Trial: 8500917
Drug: ITF 282
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF 282 (60 mg iron once daily for children ≤40 kg; twice daily for children >40 kg)
Trial: 8500917
Drug: Ferrous polystyrene
RxNorm normalized name: polystyrene sulfonate
DrugBank: Tolevamer (DB01344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous polystyrene sulphonate (52.5 mg iron once daily for children ≤40 kg; twice daily for children >40 kg)
Trial: 3319629
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training plus individual relaxation and breathing therapy (treatment A)
Trial: 28090293
Drug: Oral treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral treprostinil (up-titrated from 0.25 mg twice daily)
Trial: 20450357
Drug: mod SLA
RxNorm normalized name: slash pine pollen extract
DrugBank: Pinus elliottii pollen (DB10747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mod SLA implants
Trial: 16189077
Drug: Single 2.0-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2.0-g oral dose of azithromycin microspheres (n = 213)
Trial: 16189077
Drug: 7-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7-day regimen of levofloxacin (500 mg/day) (n = 214)
Trial: 12549813
Drug: Telephone contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone contact and physician's letter combination
Trial: 12549813
Drug: In-person counseling
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-person counseling and physician's letter combination
Trial: 10381107
Drug: Calcium mupirocin
RxNorm normalized name: Mupirocin Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium mupirocin ointment
Trial: 8873694
Drug: Isosorbide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isosorbide (20 mg by mouth t.i.d.)
Trial: 8873694
Drug: Nicardipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (20 mg by mouth t.i.d.)
Trial: 1998848
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg stanozolol intramuscularly 24 hours before operation, followed by 5 mg stanozolol orally twice daily for 6 weeks
Trial: 1998848
Drug: Placebo intramuscularly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intramuscularly 24 hours before operation, followed by placebo orally twice daily for 6 weeks
Trial: 27316679
Drug: Yirui capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yirui capsule
Trial: 24733515
Drug: Stepped collaborative
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stepped collaborative care intervention including motivational interviewing, medication, and cognitive behavioral therapy targeting PTSD and depressive symptoms.
Trial: 16782910
Drug: PCV chemotherapy
RxNorm normalized name: PCV
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCV chemotherapy plus radiotherapy (RT), n = 147
Trial: 14567804
Drug: Triptorelin depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin depot 11.25 mg 3 months before surgery (group A)
Trial: 9096431
Drug: Tamoxifen (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (40 mg/day) for 1 month
Trial: 25360652
Drug: Ulinastatin (intravenous)
RxNorm normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (intravenous)
Trial: 11961025
Drug: Continue triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue triple drug therapy (Control)
Trial: 7553634
Drug: 2B1 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2B1 at 1.0 mg/m2
Trial: 7553634
Drug: 2B1 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2B1 at 2.5 mg/m2
Trial: 7553634
Drug: 2B1 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2B1 at 5.0 mg/m2
Trial: 7553634
Drug: 2B1 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2B1 (all doses)
Trial: 2183632
Drug: Intravenous caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous caffeine pretreatment
Trial: 2183632
Drug: Electrical stimulus
RxNorm normalized name: Limulus polyphemus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulus intensity dosing
Trial: 7392905
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of Dexedrine per 70 kg of body weight
Trial: 31372757
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (100 mcg/day)
Trial: 21747085
Drug: Edrecolomab (five
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrecolomab (five infusions at 28-day intervals)
Trial: 21747085
Drug: Observation without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation without adjuvant therapy
Trial: 19267710
Drug: New insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New insulin treatment (group III, n = 245)
Trial: 19267710
Drug: Insulin before
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin before inclusion continued during the first year of follow up (group IV, n = 271)
Trial: 17114657
Drug: Etoposide 100
RxNorm normalized name: etoposide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide 100 mg/m2 on days 1-3 and cisplatin 80 mg/m2 on day 1 with concurrent twice-daily thoracic radiotherapy (TRT) (1.5 Gy per fraction, total dose of 45 Gy) followed by irinotecan 60 mg/m2 on days 1, 8, and 15 and cisplatin 60 mg/m2 on day 1 of a 4-week cycle
Trial: 14618645
Drug: Budesonide or
RxNorm normalized name: budesonide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide or Nedocromil (anti-inflammatory therapy)
Trial: 8796410
Drug: i.v. bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. bolus of 1 g/kg of 25% albumin over 4 h, repeated after 24 and 48 h
Trial: 8796410
Drug: Continuous 24-h
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 24-h infusion of 1 g/kg of 25% albumin throughout the 60-h study period
Trial: 1320259
Drug: ORG 2766
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORG 2766 (20 mg, 4 capsules daily for six weeks)
Trial: 1320259
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 capsules daily for six weeks)
Trial: 3881948
Drug: Aztreonam 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam 0.5 to 1 g twice daily
Trial: 3881948
Drug: Aztreonam 1
RxNorm normalized name: aztreonam 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam 1 g three times daily
Trial: 3881948
Drug: Cefamandole 1
RxNorm normalized name: cefamandole 1 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole 1 g three times daily
Trial: 3881948
Drug: Aztreonam 1
RxNorm normalized name: aztreonam 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam 1 to 6 g per day for eight days
Trial: 27456983
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor monotherapy (80% darunavir, 14% lopinavir, 6% other)
Trial: 28495562
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor monotherapy
Trial: 22310542
Drug: Transmitted drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmitted drug resistance mutations
Trial: 20178875
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (WM) - Terazosin Hydrochloride Hytrin (THH)
Trial: 20178875
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) - herbal Saxifrage tablet (HST)
Trial: 20178875
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (WM and TCM)
Trial: 15251662
Drug: Levothyroxine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine (1.5 to 2.0 mg/kg of body weight daily)
Trial: 7734104
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ICR
Trial: 7734104
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ICR
Trial: 7734104
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg ICR
Trial: 7734104
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ICR
Trial: 2390689
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 5 FU
Trial: 2390689
Drug: Intraperitoneal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal administration of 5 FU
Trial: 31987536
Drug: Phyllanthus amarus
RxNorm normalized name: Phyllanthus amarus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllanthus amarus nanoparticle gel applied by phonophoresis (PP)
Trial: 31987536
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy (UT)
Trial: 31469816
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab (first-line treatment)
Trial: 31469816
Drug: Nivolumab (second-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (second-line treatment)
Trial: 28492860
Drug: Anti-VEGF treatment
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-VEGF treatment prior to study participation
Trial: 22717102
Drug: OPRM1 genotype
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPRM1 genotype (G allele presence) among non-Hispanic whites
Trial: 22717102
Drug: OPRM1 genotype
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPRM1 genotype (G allele presence) among Hispanics
Trial: 22717102
Drug: OPRM1 genotype
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPRM1 genotype (G allele presence) among African Americans
Trial: 15488105
Drug: Randomized treatment
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized treatment efficacy trials
Trial: 7812072
Drug: 800 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/day Calcium supplements (two different forms)
Trial: 7812072
Drug: Calcium supplements
RxNorm normalized name: CALCIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplements (in fractured patients)
Trial: 2338120
Drug: Diclofenac hydroxyethylpyrrolidine
RxNorm normalized name: diclofenac hydroxyethylpyrrolidine 1.292 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac hydroxyethylpyrrolidine (DIEP) 2 X 50 mg
Trial: 2338120
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 2 X 50 mg
Trial: 28975429
Drug: Intra-oral cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-oral cooling device
Trial: 23639862
Drug: Bowman Birk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowman Birk Inhibitor Concentrate (BBIC)
Trial: 20693809
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy + infliximab
Trial: 19805692
Drug: Oral satraplatin
RxNorm normalized name: satraplatin
DrugBank: Satraplatin (DB04996)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral satraplatin (80 mg/m² on days 1 to 5 of a 35-day cycle) and prednisone (5 mg twice daily)
Trial: 19805692
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and prednisone (5 mg twice daily)
Trial: 15875093
Drug: Risedronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (5 mg/daily)
Trial: 10192656
Drug: Oestrogen replacement
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen replacement therapy (2 mg of 17-beta-oestradiol orally for 3 months)